Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets


Out-
      side
 



 
 'Magnevist®' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Magnevist®' found in 2 terms [] and 5 definitions []
1 - 5 (of 7)     next
Result Pages : [1]  [2]
Searchterm 'Magnevist®' was also found in the following services: 
spacer
Resources  (1)  
 
Magnevist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Magnevist® is a paramagnetic ionic contrast agent for use in magnetic resonance imaging. Contrast enhanced MRI with Magnevist® allows additional diagnostic information of tumors, inflammation and vascular lesions and the determination or differentiation of such lesions.
The contrast enhancing effect is produced by the di-N-methylglucamine salt of gadopentetate (Gd-DTPA), the gadolinium complex of diethylenetriamine pentaacetic acid. Magnevist® has the strongest effect on T1 weighted images, by increasing T1 signal intensity in tissues where Magnevist® has accumulated.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Ionic Intravenous Contrast Agents and Gadopentetate Dimeglumine.

Drug Information and Specification
NAME OF COMPOUND Gadopentetate dimeglumine, Gd-DTPA
DEVELOPER Bayer Schering Pharma AG, Germany
CENTRAL MOIETY Gd3+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.4, r2=3.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 1960 mosm/kgH2O
CONCENTRATION 0.5 mol/L
DOSAGE 0.1-0.3 mmol/kg / 0.2-0.6 mL/kg
PREPARATION Finished product
INDICATION Neuro/whole body
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 5, 10, 15, 20 and 100 mL bulk package
Pre-filled syringes of 10, 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA, Canada Magnevist® for sale Bayer HealthCare Pharmaceuticals
Asia Magnevist® for sale Bayer Schering Pharma AG
EU Magnevist® for sale Bayer Schering Pharma AG
Turkey Magnevist®, Magnograf for sale Bayer Schering Pharma AG
Australia Magnevist® for sale Bayer Schering Pharma AG

spacer
 
• Share the entry 'Magnevist®':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection - WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
May 2009   by berlex.bayerhealthcare.com    
Magnevist Package Insert
2000
  News & More:
Magnevist Prescription Drug Discount Sources
   by www.institutedc.org    
Neuro-Oncology - Diagnosis MRI with Gd-DTPA
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
Searchterm 'Magnevist®' was also found in the following services: 
spacer
Radiology  (1) Open this link in a new windowUltrasound  (1) Open this link in a new window
Magnevist® EnteralInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Magnevist® enteral (Gadopentetate) is a Gd-DTPA solution for use as a gastrointestinal contrast agent to visualize the bowel in MRI scans.
See also Positive Oral Contrast Agents and Gadopentetate Gastrointestinal.

Drug Information and Specification
NAME OF COMPOUND Gadopentetate dimeglumine, Gd-DTPA
DEVELOPER Bayer Schering Pharma AG
CENTRAL MOIETY Gd3+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY Paramagnetic
PHARMACOKINETIC Gastrointestinal
OSMOLALITY
CONCENTRATION 0.001 mol/L
DOSAGE 100 ml oral
PREPARATION Finished product
INDICATION Bowel marking
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vial of 100 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
USA Magnevist® enteral for sale Bayer HealthCare Pharmaceuticals
EU Magnevist® enteral for sale Bayer Schering Pharma AG

spacer

• View the DATABASE results for 'Magnevist® Enteral' (3).Open this link in a new window

MRI Resources 
Libraries - Guidance - Supplies - Process Analysis - Sequences - Distributors
 
Bayer Schering Pharma AGMRI Resource Directory:
 - Manufacturers -
 
www.bayerscheringpharma.de/scripts/pages/en/index.php The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

Product Information
TRADE NAME
(LOCAL DISTRIBUTION)
FOR SALE FOR SALE /
DEVELOPMENT
DEVELOPMENT
Magnevist® enteral
Magnevist®
Gadovist®
Resovist® -
Primovist™,Eovist®
Vasovist® -
Gadofluorine
Gadophrin
Gadomer 17
Gd-DTPA-Polylysine
Supravist™

Contact Information
MAIL Bayer Schering Pharma AG
51368 Leverkusen
GERMANY
PHONE +49-30-46-81-2431
FAX +49-30-46-81-8195
ONLINE www.bayerscheringpharma.de/scripts/pages/en/index.php
spacer

• View the DATABASE results for 'Bayer Schering Pharma AG' (22).Open this link in a new window


• View the NEWS results for 'Bayer Schering Pharma AG' (25).Open this link in a new window.
 
Further Reading:
  News & More:
Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments
Thursday, 21 October 2004   by www.news-medical.net    
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
Searchterm 'Magnevist®' was also found in the following services: 
spacer
Resources  (1)  
 
Extracellular Fluid AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
The contrast agents are either renal or hepatically excreted media, which stay in the intravascular/extracellular tissue compartment. The enhancement in the blood continues for as long as the contrast agent remains in the blood stream.
E.g. Dotarem®, Magnevist®, Omniscan®, ProHance®.
See Contrast Medium, Contrast Agents and Blood Pool Agents.
spacer

• View the DATABASE results for 'Extracellular Fluid Agents' (2).Open this link in a new window

Searchterm 'Magnevist®' was also found in the following services: 
spacer
Radiology  (1) Open this link in a new windowUltrasound  (1) Open this link in a new window
Gadopentetate DimeglumineInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: Gd-DTPA, generic name: Gadopentetate dimeglumine, chemical compound: Gadolinium-diethylenetriaminepentaacetic acid
Gadopentetate dimeglumine was introduced in 1981, as the first paramagnetic MRI contrast agent (ionic). The Gd-induced dipole dipole interactions lead to shortening of T1, which results in contrast enhancement on T1 weighted images. The used metal ion Gd3+ (gadolinium) is toxic, and therefore bound in the renally excreted DTPA chelate, a very stable complex. The Gd-complex also induce susceptibility effects, as a result of the magnetic field gradient between the contrast agent in the blood vessels and the surrounding tissue, that lead to shortening of T2 or T2*.
Following intravenous administration, the compound is distributed rapidly in the extracellular space and is eliminated unchanged by glomerular filtration via the kidneys. Up to 6 hours, post injection an average of 83% of the dose is eliminated renal.
See also Magnevist®, Gadolinium and Contrast Agents.

spacer

• View the DATABASE results for 'Gadopentetate Dimeglumine' (5).Open this link in a new window

 
Further Reading:
  Basics:
Magnevist Package Insert
2000
Gadopentetic acid
   by en.wikipedia.org    
MRI Resources 
NMR - Functional MRI - Open Directory Project - IR - Image Quality - Manufacturers
 
     1 - 5 (of 7)     next
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Acoustic Noise Reduction (Silent, Quiet, etc.) :
cannot get better 
is in its first steps 
is done by earplugs, headphones 
must get better 
is bad, I miss something 
is unnecessary 

Look
      Ups





Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2016 SoftWays. All rights reserved. [ 21 January 2017]
Terms of Use | Privacy Policy | Advertising
 [last update: 2017-01-13 03:47:00]